Amdokitug

安沐奇塔单抗

Report date: 2026/03/24 20:00:35

Base Information

Drug NameAmdokitug
Drug Alias Name重组抗IL-17A人源化单克隆抗体注射液益赛拓608SSGJ-608
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[6] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2026/02/10
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A